Trevi jumps as chronic cough therapy succeeds mid-stage trial

Trevi Therapeutics

10/03/2025 10:43

** Shares of therapy developer Trevi Therapeutics TRVI.O rise 21.9% to $5.24 premarket

** Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough

** Says therapy showed statistically significant reduction in 24-hour cough frequency

** Currently, there are no approved treatments in the U.S. for coughing bouts that don't have no identifiable cause or those that persist despite treatment of underlying conditions

** GSK GSK.L has a chronic cough treatment in development, and Merck has an experimental drug for the disease which faced two FDA rejections in the past

** Up to last close, TRVI up 45.8% in the last 12 months

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))